Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic

The majority of breast cancers express the estrogen receptor (ER) and for this group of patients, endocrine therapy is the cornerstone of systemic treatment. However, drug resistance is common and a focus for breast cancer preclinical and clinical research. Over the past 2 decades, the PI3K/Akt/mTOR...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Exploration of targeted anti-tumor therapy Ročník 3; číslo 2; s. 172 - 199
Hlavní autoři: Skolariki, Aglaia, D’Costa, Jamie, Little, Martin, Lord, Simon
Médium: Journal Article
Jazyk:angličtina
Vydáno: Open Exploration 2022
Open Exploration Publishing Inc
Témata:
breast cancer
endocrine therapy
pi3k/akt/mtor pathway
Review
ISSN:2692-3114, 2692-3114
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:The majority of breast cancers express the estrogen receptor (ER) and for this group of patients, endocrine therapy is the cornerstone of systemic treatment. However, drug resistance is common and a focus for breast cancer preclinical and clinical research. Over the past 2 decades, the PI3K/Akt/mTOR axis has emerged as an important driver of treatment failure, and inhibitors of mTOR and PI3K are now licensed for the treatment of women with advanced ER-positive breast cancer who have relapsed on first-line hormonal therapy. This review presents the preclinical and clinical data that led to this new treatment paradigm and discusses future directions.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:2692-3114
2692-3114
DOI:10.37349/etat.2022.00078